

**Table 1. Approved drugs and commonly used dosages for treatment of chronic HCV infection.**

<b>Drug</b>	<b>Trade name (manufacturer)</b>	<b>Commonly used dosages</b>
Interferon alfa-2a	<ul style="list-style-type: none"> <li>• Roferon (Roche)</li> </ul>	3 million units 3 times per week
Interferon alfa-2b	<ul style="list-style-type: none"> <li>• Intron A (Schering-Plough)</li> </ul>	3 million units 3 times per week
Interferon alfacon-1	<ul style="list-style-type: none"> <li>• Infergen (Intermune)</li> </ul>	9-15 mcg 3 times a week
Ribavirin	<ul style="list-style-type: none"> <li>• Rebetol (Schering-Plough)</li> <li>• Copegus (Roche)</li> </ul>	800 – 1200 mg per day
Peginterferon alfa-2a	<ul style="list-style-type: none"> <li>• Pegasys (Roche)</li> </ul>	1.5 mcg/kg weekly
Peginterferon alfa-2b	<ul style="list-style-type: none"> <li>• PEG-Intron (Schering-Plough)</li> </ul>	180 mcg weekly

The dosages are provided for information purposes only. Health care providers are advised to familiarize themselves with these drugs usage, dosages and adverse events, including dose-related toxicities, as provided in the package inserts of each drug.